User:Mr. Ibrahem/Emtricitabine/tenofovir

Emtricitabine/tenofovir (FTC/TDF), sold under the brand name Truvada among others, is a fixed-dose combination medication used to treat and prevent HIV/AIDS. It contains the antiretroviral medications emtricitabine and tenofovir disoproxil. For treatment, it is used either alone or together with other antiretroviral medications. For prevention before exposure, in those who are at high risk, it is recommended with safe sex practices. It does not cure HIV/AIDS. Emtricitabine/tenofovir is taken by mouth.

Common side effects include headache, tiredness, trouble sleeping, abdominal pain, weight loss, and rash. Serious side effects may include high blood lactate levels and enlargement of the liver. Use of this medication during pregnancy does not appear to harm the baby, but has not been well studied.

Emtricitabine/tenofovir was approved for medical use in the United States in 2004. It is on the World Health Organization's List of Essential Medicines. In the United States, emtricitabine/tenofovir is under patent until 2020, but is available as a generic in the rest of the world. The 2015 wholesale cost in the developing world is about US$6 to US$8 per month. In the United States, as of 2019, the wholesale cost is about US$1,710 per month. In Australia, this amount costs about US$8.